<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453672</url>
  </required_header>
  <id_info>
    <org_study_id>SB8-G11-NHV</org_study_id>
    <secondary_id>2015-001026-41</secondary_id>
    <nct_id>NCT02453672</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects</brief_title>
  <official_title>A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Bevacizumab (SB8, EU Sourced Avastin®, and US Sourced Avastin®) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of
      Bevacizumab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the
      Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of
      Bevacizumab (SB8, EU Sourced Avastin®, and US Sourced Avastin®) in Healthy Male Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)</measure>
    <time_frame>0 to 2016 hours after start of infusion</time_frame>
    <description>0 (pre-dose), 0.75, 1.5 (end of infusion), 3, 6, 12, 24, 48, and 96 hours, then at Day 8 (168 h), 15 (336 h), 22 (504 h), 29 (672 h), 43 (1008 h), 57 (1344 h), 71 (1680 h), and 85 (2016 h) after start of infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>0 to 2016 hours after start of infusion</time_frame>
    <description>0 (pre-dose), 0.75, 1.5 (end of infusion), 3, 6, 12, 24, 48, and 96 hours, then at Day 8 (168 h), 15 (336 h), 22 (504 h), 29 (672 h), 43 (1008 h), 57 (1344 h), 71 (1680 h), and 85 (2016 h) after start of infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Serum Concentration (Cmax)</measure>
    <time_frame>0 to 2016 hours after start of infusion</time_frame>
    <description>0 (pre-dose), 0.75, 1.5 (end of infusion), 3, 6, 12, 24, 48, and 96 hours, then at Day 8 (168 h), 15 (336 h), 22 (504 h), 29 (672 h), 43 (1008 h), 57 (1344 h), 71 (1680 h), and 85 (2016 h) after start of infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax (Tmax)</measure>
    <time_frame>0 to 2016 hours after start of infusion</time_frame>
    <description>0 (pre-dose), 0.75, 1.5 (end of infusion), 3, 6, 12, 24, 48, and 96 hours, then at Day 8 (168 h), 15 (336 h), 22 (504 h), 29 (672 h), 43 (1008 h), 57 (1344 h), 71 (1680 h), and 85 (2016 h) after start of infusion.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SB8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB8, single dose of 3 mg/kg, IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU Sourced Avastin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US Sourced Avastin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US Sourced Avastin®, single dose of 3 mg/kg, IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB8</intervention_name>
    <description>SB8, proposed bevacizumab biosimilar</description>
    <arm_group_label>SB8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU sourced Avastin®</intervention_name>
    <description>EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
    <arm_group_label>EU Sourced Avastin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US Sourced Avastin®</intervention_name>
    <description>US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
    <arm_group_label>US Sourced Avastin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects

          -  Have body weight between 65.0-90.0 kg (inclusive) and body mass index between
             20.0-29.9 kg/m2 (inclusive)

        Exclusion Criteria:

          -  Have a history of hypersensitivity or allergic reactions to bevacizumab or to any of
             the excipients

          -  Have a history of and/or current clinically significant gastrointestinal, renal,
             hepatic, cardiovascular, haematological, pulmonary, neurologic, metabolic,
             psychiatric, or allergic disease excluding mild asymptomatic seasonal allergies

          -  Have a history of arterial thromboembolic events including cerebrovascular accidents,
             transient ischaemic attacks, and myocardial infarction

          -  Have a history of and/or current cardiac disease

          -  Have previously been exposed to vascular endothelial growth factor (VEGF) antibody,
             any other antibody, or protein targeting the VEGF receptor

          -  Have a history of cancer including lymphoma, leukaemia, and skin cancer.

          -  Have received live vaccine(s) within 30 days prior to Screening visit or who will
             require a vaccine(s) between Screening and the end of study visit

          -  Have taken medication with a half-life of &gt; 24 hours within 30 days or 10 half-lives
             of the medication prior to the IP administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Investigational Site</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <results_first_submitted>October 9, 2018</results_first_submitted>
  <results_first_submitted_qc>February 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2019</results_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SB8 (Proposed Bevacizumab Biosimilar)</title>
          <description>SB8, single dose of 3 mg/kg, IV infusion
SB8: SB8, proposed bevacizumab biosimilar</description>
        </group>
        <group group_id="P2">
          <title>EU Sourced Avastin®</title>
          <description>EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
EU sourced Avastin®: EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
        </group>
        <group group_id="P3">
          <title>US Sourced Avastin®</title>
          <description>US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
US Sourced Avastin®: US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SB8 (Proposed Bevacizumab Biosimilar)</title>
          <description>SB8, single dose of 3 mg/kg, IV infusion
SB8: SB8, proposed bevacizumab biosimilar</description>
        </group>
        <group group_id="B2">
          <title>EU Sourced Avastin®</title>
          <description>EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
EU sourced Avastin®: EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
        </group>
        <group group_id="B3">
          <title>US Sourced Avastin®</title>
          <description>US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
US Sourced Avastin®: US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" spread="9.24"/>
                    <measurement group_id="B2" value="39.5" spread="10.45"/>
                    <measurement group_id="B3" value="38.9" spread="9.32"/>
                    <measurement group_id="B4" value="40.9" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)</title>
        <description>0 (pre-dose), 0.75, 1.5 (end of infusion), 3, 6, 12, 24, 48, and 96 hours, then at Day 8 (168 h), 15 (336 h), 22 (504 h), 29 (672 h), 43 (1008 h), 57 (1344 h), 71 (1680 h), and 85 (2016 h) after start of infusion.</description>
        <time_frame>0 to 2016 hours after start of infusion</time_frame>
        <population>Among the subjects discountinued, subjects with major protocol deviations were excluded from the PK population for the PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>SB8 (Proposed Bevacizumab Biosimilar)</title>
            <description>SB8, single dose of 3 mg/kg, IV infusion
SB8: SB8, proposed bevacizumab biosimilar</description>
          </group>
          <group group_id="O2">
            <title>EU Sourced Avastin®</title>
            <description>EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
EU sourced Avastin®: EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
          </group>
          <group group_id="O3">
            <title>US Sourced Avastin®</title>
            <description>US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
US Sourced Avastin®: US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)</title>
          <description>0 (pre-dose), 0.75, 1.5 (end of infusion), 3, 6, 12, 24, 48, and 96 hours, then at Day 8 (168 h), 15 (336 h), 22 (504 h), 29 (672 h), 43 (1008 h), 57 (1344 h), 71 (1680 h), and 85 (2016 h) after start of infusion.</description>
          <population>Among the subjects discountinued, subjects with major protocol deviations were excluded from the PK population for the PK analysis.</population>
          <units>h·μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25354.4" spread="4833.10"/>
                    <measurement group_id="O2" value="28896.8" spread="6221.62"/>
                    <measurement group_id="O3" value="28684.8" spread="5425.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)</title>
        <description>0 (pre-dose), 0.75, 1.5 (end of infusion), 3, 6, 12, 24, 48, and 96 hours, then at Day 8 (168 h), 15 (336 h), 22 (504 h), 29 (672 h), 43 (1008 h), 57 (1344 h), 71 (1680 h), and 85 (2016 h) after start of infusion.</description>
        <time_frame>0 to 2016 hours after start of infusion</time_frame>
        <population>Among the subjects discountinued, subjects with major protocol deviations were excluded from the PK population for the PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>SB8 (Proposed Bevacizumab Biosimilar)</title>
            <description>SB8, single dose of 3 mg/kg, IV infusion
SB8: SB8, proposed bevacizumab biosimilar</description>
          </group>
          <group group_id="O2">
            <title>EU Sourced Avastin®</title>
            <description>EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
EU sourced Avastin®: EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
          </group>
          <group group_id="O3">
            <title>US Sourced Avastin®</title>
            <description>US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
US Sourced Avastin®: US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)</title>
          <description>0 (pre-dose), 0.75, 1.5 (end of infusion), 3, 6, 12, 24, 48, and 96 hours, then at Day 8 (168 h), 15 (336 h), 22 (504 h), 29 (672 h), 43 (1008 h), 57 (1344 h), 71 (1680 h), and 85 (2016 h) after start of infusion.</description>
          <population>Among the subjects discountinued, subjects with major protocol deviations were excluded from the PK population for the PK analysis.</population>
          <units>h·μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24199.2" spread="4367.53"/>
                    <measurement group_id="O2" value="27342.2" spread="5374.53"/>
                    <measurement group_id="O3" value="27177.9" spread="4770.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Serum Concentration (Cmax)</title>
        <description>0 (pre-dose), 0.75, 1.5 (end of infusion), 3, 6, 12, 24, 48, and 96 hours, then at Day 8 (168 h), 15 (336 h), 22 (504 h), 29 (672 h), 43 (1008 h), 57 (1344 h), 71 (1680 h), and 85 (2016 h) after start of infusion.</description>
        <time_frame>0 to 2016 hours after start of infusion</time_frame>
        <population>Among the subjects discountinued, subjects with major protocol deviations were excluded from the PK population for the PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>SB8 (Proposed Bevacizumab Biosimilar)</title>
            <description>SB8, single dose of 3 mg/kg, IV infusion
SB8: SB8, proposed bevacizumab biosimilar</description>
          </group>
          <group group_id="O2">
            <title>EU Sourced Avastin®</title>
            <description>EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
EU sourced Avastin®: EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
          </group>
          <group group_id="O3">
            <title>US Sourced Avastin®</title>
            <description>US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
US Sourced Avastin®: US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration (Cmax)</title>
          <description>0 (pre-dose), 0.75, 1.5 (end of infusion), 3, 6, 12, 24, 48, and 96 hours, then at Day 8 (168 h), 15 (336 h), 22 (504 h), 29 (672 h), 43 (1008 h), 57 (1344 h), 71 (1680 h), and 85 (2016 h) after start of infusion.</description>
          <population>Among the subjects discountinued, subjects with major protocol deviations were excluded from the PK population for the PK analysis.</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.259" spread="14.6999"/>
                    <measurement group_id="O2" value="76.059" spread="11.7053"/>
                    <measurement group_id="O3" value="76.485" spread="16.9916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Cmax (Tmax)</title>
        <description>0 (pre-dose), 0.75, 1.5 (end of infusion), 3, 6, 12, 24, 48, and 96 hours, then at Day 8 (168 h), 15 (336 h), 22 (504 h), 29 (672 h), 43 (1008 h), 57 (1344 h), 71 (1680 h), and 85 (2016 h) after start of infusion.</description>
        <time_frame>0 to 2016 hours after start of infusion</time_frame>
        <population>Among the subjects discountinued, subjects with major protocol deviations were excluded from the PK population for the PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>SB8 (Proposed Bevacizumab Biosimilar)</title>
            <description>SB8, single dose of 3 mg/kg, IV infusion
SB8: SB8, proposed bevacizumab biosimilar</description>
          </group>
          <group group_id="O2">
            <title>EU Sourced Avastin®</title>
            <description>EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
EU sourced Avastin®: EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
          </group>
          <group group_id="O3">
            <title>US Sourced Avastin®</title>
            <description>US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
US Sourced Avastin®: US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Cmax (Tmax)</title>
          <description>0 (pre-dose), 0.75, 1.5 (end of infusion), 3, 6, 12, 24, 48, and 96 hours, then at Day 8 (168 h), 15 (336 h), 22 (504 h), 29 (672 h), 43 (1008 h), 57 (1344 h), 71 (1680 h), and 85 (2016 h) after start of infusion.</description>
          <population>Among the subjects discountinued, subjects with major protocol deviations were excluded from the PK population for the PK analysis.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.639" spread="2.1885"/>
                    <measurement group_id="O2" value="3.638" spread="2.4261"/>
                    <measurement group_id="O3" value="5.646" spread="15.6665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SB8 (Proposed Bevacizumab Biosimilar)</title>
          <description>SB8, single dose of 3 mg/kg, IV infusion
SB8: SB8, proposed bevacizumab biosimilar</description>
        </group>
        <group group_id="E2">
          <title>EU Sourced Avastin®</title>
          <description>EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
EU sourced Avastin®: EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
        </group>
        <group group_id="E3">
          <title>US Sourced Avastin®</title>
          <description>US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
US Sourced Avastin®: US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Development</name_or_title>
      <organization>Samsung Bioepis</organization>
      <phone>+82 31 8061 4534</phone>
      <email>sbregistry@samsung.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

